Plasma Cytokine Profiles in Subjects with High-Functioning Autism Spectrum Disorders

Katsuki Suzuki1*, Hideo Matsuzaki1, Keiko Iwata1, Yosuke Kameno2, Chie Shimmura2, Satomi Kawai3, Yujiro Yoshihara4, Tomoyasu Wakuda2, Kiyokazu Takebayashi1, Shu Takagai2, Kaori Matsumoto1, Kenji J. Tsuchiya1, Yasuhide Iwata2, Kazuhiko Nakamura2, Masatsugu Tsujii5, Toshirou Sugiyama6, Norio Mori1,2

1 Research Center for Child Mental Development, Hamamatsu University School of Medicine, Hamamatsu, Japan, 2 Department of Psychiatry and Neurology, Hamamatsu University School of Medicine, Hamamatsu, Japan, 3 Department of Psychiatry, National Hospital Organization Tenryu Hospital, Hamamatsu, Japan, 4 Department of Psychiatry, Koujin Hospital, Nagoya, Japan, 5 Faculty of Sociology, Chukyo University, Toyota, Japan, 6 Department of Child and Adolescent Psychiatry, Hamamatsu University School of Medicine, Hamamatsu, Japan

**Abstract**

**Background:** Accumulating evidence suggests that dysregulation of the immune system is involved in the pathophysiology of autism spectrum disorders (ASD). The aim of the study was to explore immunological markers in peripheral plasma samples from non-medicated subjects with high-functioning ASD.

**Methodology/Principal Findings:** A multiplex assay for cytokines and chemokines was applied to plasma samples from male subjects with high-functioning ASD (n = 28) and matched controls (n = 28). Among a total of 48 analytes examined, the plasma concentrations of IL-1β, IL-1RA, IL-5, IL-8, IL-12(p70), IL-13, IL-17 and GRO-α were significantly higher in subjects with ASD compared with the corresponding values of matched controls after correction for multiple comparisons.

**Conclusion/Significance:** The results suggest that abnormal immune responses as assessed by multiplex analysis of cytokines may serve as one of the biological trait markers for ASD.

**Citation:** Suzuki K, Matsuzaki H, Iwata K, Kameno Y, Shimmura C, et al. (2011) Plasma Cytokine Profiles in Subjects with High-Functioning Autism Spectrum Disorders. PLoS ONE 6(5): e20470. doi:10.1371/journal.pone.0020470

**Editor:** Takeo Yoshikawa, Rikagaku Kenkyusho Brain Science Institute, Japan

**Received April 6, 2011; Accepted April 26, 2011; Published May 27, 2011**

**Copyright:** © 2011 Suzuki et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This work was supported by a Grant-in-Aid for Scientific Research (B) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan to KS (#22390022). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

*E-mail: k-suzuki@hama-med.ac.jp*

**Introduction**

Autism spectrum disorders (ASD) are a group of neurodevelopmental disorders characterized by pervasive abnormalities in social interaction and communication, and repetitive and restricted behavioral patterns and interests. ASD include autistic disorder, Asperger’s disorder and pervasive developmental disorder, not otherwise specified [1]. Susceptibility to ASD is clearly attributable to genetic factors [2], but the etiology of ASD is unknown, and no biomarkers have yet been proven to be characteristic of ASD.

Accumulating evidence suggests that dysregulation of the immune system may be implicated in the pathophysiology of ASD [3,4]. For instance, postmortem studies have shown that the protein levels of tumor necrosis factor α (TNF-α) and interleukin (IL)-6 [5], as well as the number of activated microglia [6], are significantly increased in the brains of subjects with ASD compared to controls. In addition, lipopolysaccharide-stimulated productions of TNF-α and IL-6 have been shown to be greater in peripheral blood mononuclear cells from subjects with ASD than those from controls [7]. And increased levels of inflammatory cytokines have been detected even in peripheral samples such as serum [8–13] or plasma [14–18] of patients with ASD. These findings suggest that the pattern of plasma cytokine levels could serve as a useful biological marker of ASD. However, the results of the previous studies addressing serum or plasma levels of cytokines in ASD appear to be inconsistent, probably due to variations in the experimental designs, diagnostic criteria used and age ranges of the subjects, although another possible explanation is that these inconsistencies reflect the heterogeneity of the ASD themselves.

Recent advances in multiplex technologies have enabled measurement of multiple analytes simultaneously. Multiplexing provides data on a large number of analytes, even when the sample volumes are limited [19,20]. In this study, we used a multiplex assay to measure a series of 48 cytokines in plasma samples from subjects with high-functioning ASD in comparison with matched control subjects. A recent systemic serum proteome profiling study reported that males and females with Asperger’s disorder have distinct biomarker fingerprints [11]. Therefore, to prevent any potential confounding effect of sex, we recruited only males in this study. Also, cytokine profiles were only determined in the ASD male subjects who were more than 6 years of age, because a multiplex analysis of cytokines in plasma samples obtained from children less than 5 years of age (the majority of whom were males) was recently reported [14].
Results

Subjects

The characteristics of all participants are summarized in Table 1. There was no significant difference in the distribution of age (t = 0.26, P = 0.79) or full IQ (t = 0.46, P = 0.65) between the two groups, indicating that the subject matching was successful. Several pro-inflammatory cytokines, including TNF-α and IL-6, are known to be produced by adipose tissue, and the plasma levels of these cytokines have been correlated with parameters of obesity [21]. Therefore, we measured the weight and height of all the participants, and the body mass index (BMI) was calculated. There were no significant inter-group differences in the weight, height, or BMI. In subjects with ASD, 21 subjects with ASD were diagnosed with autistic disorder and the remaining 7 were considered to have PDD-NOS, according to the Autism Diagnostic Interview-Revised (ADI-R) [22].

Plasma levels of cytokines and chemokines by multiplex assay kits

The comparison of cytokine and chemokine detection is summarized in Table 2. Among a total of 48 analytes, plasma concentrations of IL-2, IL-15, basic FGF, GM-CSF and LIF did not reach the detection range in either group, and these five analytes were excluded from further analyses. Plasma levels of IL-1β, IL-1RA, IL-5, IL-6, IL-12(p70), IL-13, IL-17 and GRO-α were significantly higher in subjects with ASD compared with the corresponding values of matched controls after correction for multiple comparisons. Plasma levels of IL-4, IL-7, G-CSF, IFN-γ, MIP-1β, PDGF-BB, TNF-α, HGF and VEGF tended to be greater in the ASD group than in the control groups, but after correction for multiple comparisons, the differences did not reach the level of statistical significance. The mean levels of fold changes of the cytokines that differed significantly between the two groups are summarized in Figure 1.

We then examined the correlations between plasma levels of IL-1β, IL-1RA, IL-5, IL-12(p70), IL-13, IL-17 and GRO-α and clinical variables in the subjects with ASD. There were no statistically significant correlations between the plasma levels of analytes and clinical variables, including age, weight, height, BMI, IQ (full, verbal and performance) and severities in autistic symptoms as assessed by the ADI-R. When correlation coefficients were evaluated among the 7 analytes that showed significant elevation in ASD, there were significant correlations between IL-1β and IL-1RA (Pearson’s r = .626, P<0.001), between IL-5 and IL-13 (r = .497, P = 0.007), between IL-13 and IL-12(p70) (r = .747, P<0.001) and between IL-6 and GRO-α (r = .415, P = 0.026).

Discussion

In the present study, plasma levels of IL-1β, IL-1RA, IL-5, IL-6, IL-12(p70), IL-13, IL-17 and GRO-α in the high-functioning male subjects with ASD were significantly higher than those of carefully matched control subjects. Our participants with ASD showed no signs or symptoms implying inflammatory diseases and were similar in parameters of obesity, including BMI, to controls. Thus, it is likely that the elevations in plasma levels of those analytes were significantly associated with the diagnosis of ASD. These results are in line with the studies mentioned above, which reported altered immune responses in individuals with ASD [3,4]. The fold changes of each analyte, however, ranged from 1.5 to 2.5, which values were far lower than those of inflammatory or autoimmune diseases. In addition, none of the analyte plasma levels were correlated with the severity of autistic symptoms. Therefore, it was suggested that the elevation of cytokines observed here may represent an abnormal steady-state immune response in subjects with ASD, and that such a multiplex analysis of cytokines may serve as one of the biological trait markers for the disorder.

Plasma levels of IL-1β and IL-1RA were elevated in ASD

IL-1β is a pro-inflammatory cytokine produced by various sources, including monocytes, macrophages, dendritic cells, neutrophil leukocytes and endothelial cells [23]. Among previous reports, two studies that examined serum levels of selected cytokines, i.e., IL-1 [12] and IL-1β [24], in autistic subjects reported no change. However, two other recent studies using multiplex assay in ASD have demonstrated a significant increase in plasma IL-1β levels in 2- to 5-year-old children with ASD [14] or in serum IL-1β levels in adults with Asperger’s syndrome [11]. Given the wide variety of functions of IL-1β as an important mediator of inflammatory response, including cell proliferation, differentiation and apoptosis [23], it is not surprising that this cytokine can serve as a marker for abnormal response in subjects with ASD. On the other hand, IL-1RA binds to the cell surface IL-1 receptor, inhibits the activities of IL-1β, and modulates IL-1-

Table 1. Demographic and clinical characteristics.

| Characteristic | Mean (SD) [Range] | ASD, N = 28 |
|----------------|------------------|-------------|
|                | Control, N = 28  |             |
| Age, years     | 12.3 (2.3) [7–15] | 12.1 (3.3) [7–15] |
| Full IQ        | 101.5 (11.5) [82–124] | 99.6 (18.6) [72–136] |
| Height, cm     | 149.6 (12.5) [121.4–172.8] | 147.1 (17.0) [110.0–175.0] |
| Weight, kg     | 40.4 (10.6) [24.0–62.0] | 40.4 (13.2) [17.5–72.4] |
| BMI, kg/m²     | 17.7 (2.4) [14.4–25.3] | 18.1 (2.6) [13.9–24.2] |
| Scores on Autism Diagnostic Interview-Revised | | |
| Domain A (social) | N/A | 19.9 (5.2) [9–27] |
| Domain BV (communication) | N/A | 13.7 (4.0) [8–21] |
| Domain C (stereotype) | N/A | 5.6 (2.2) [3–10] |
| Domain D (age of onset) | N/A | 3.2 (1.1) [1–5] |

Abbreviations: ASD, autism spectrum disorder; IQ, intelligence quotient; BMI, body-mass index; and N/A, not applicable.

doi:10.1371/journal.pone.0020470.t001
Table 2. List of analytes in the multiplex assay.

| Analytes | Control group (n = 28) | ASD group (n = 28) | FDR- corrected P value |
|----------|------------------------|--------------------|------------------------|
|          | mean       | SD   | mean       | SD   | t value |          |
| Group I  |            |      |            |      |         |          |
| IL-1β   | 1.1        | 0.8  | 1.7        | 0.8  | -2.616  | *0.049   |
| IL-1RA  | 85.4       | 49.2 | 135.0      | 43.4 | -4.002  | *0.003   |
| IL-2     | BDR        | BDR  |            |      |         |          |
| IL-4     | 2.1        | 0.9  | 2.7        | 0.9  | -2.487  | 0.06     |
| IL-5     | 2.8        | 1.4  | 3.8        | 1.3  | -2.906  | *0.033   |
| IL-6     | 5.9        | 3.2  | 6.8        | 2.4  | -1.207  | 0.37     |
| IL-7     | 10.8       | 3.1  | 12.8       | 3.4  | -2.201  | 0.09     |
| IL-8     | 8.7        | 3.7  | 11.6       | 2.5  | -3.391  | *0.014   |
| IL-9     | 13.0       | 10.1 | 14.8       | 9.9  | -0.672  | 0.68     |
| IL-10    | 2.5        | 1.8  | 2.9        | 1.4  | -1.039  | 0.45     |
| IL-12 (p70) | 21.3     | 12.6 | 38.1       | 13.7 | -4.784  | *0.001   |
| IL-13    | 11.8       | 5.2  | 16.3       | 5.0  | -3.329  | *0.011   |
| IL-15    | BDR        | BDR  |            |      |         |          |
| IL-17    | 7.2        | 4.8  | 17.7       | 11.9 | -4.287  | *0.002   |
| Eotaxin  | 86.7       | 50.8 | 107.6      | 35.3 | -1.789  | 0.16     |
| Basic FGF | BDR      | BDR  |            |      |         |          |
| G-CSF    | 4.8        | 3.4  | 6.9        | 3.2  | -2.368  | 0.07     |
| GM-CSF   | BDR        | BDR  |            |      |         |          |
| IFN-γ    | 80.0       | 46.4 | 107.2      | 49.6 | -2.123  | 0.10     |
| IP-10    | 1912.2     | 3202.5 | 1075.1    | 322.0 | 1.376  | 0.33     |
| MCP-1    | 26.4       | 17.3 | 28.2       | 13.9 | -0.419  | 0.63     |
| MIP-1β   | 6.5        | 2.6  | 6.7        | 2.8  | 1.065   | 0.29     |
| MIP-1α   | 125.0      | 45.3 | 159.8      | 57.1 | -2.527  | 0.06     |
| PDGF-BB  | 11053.2    | 3023.3 | 12465.3   | 1548.4 | -2.200 | 0.09     |
| RANTES   | 6303.5     | 809.6 | 6103.5    | 598.4 | 1.051  | 0.46     |
| TNF-α    | 8.6        | 9.1  | 18.0       | 19.6 | 2.316   | 0.08     |
| VEGF     | 74.3       | 65.6 | 124.9      | 75.4 | -2.682  | 0.05     |
| Group II |            |      |            |      |         |          |
| CTACK    | 555.8      | 138.7 | 606.1      | 145.8 | 1.324  | 0.33     |
| GRO-α    | 60.5       | 38.3 | 99.0       | 47.4 | -3.347  | *0.013   |
| HGF      | 213.1      | 83.5 | 266.0      | 66.9 | -2.619  | 0.06     |
| IFN-α2   | 38.4       | 11.1 | 38.1       | 8.2  | 0.150   | 0.92     |
| IL-1α    | 0.5        | 0.4  | 0.6        | 0.4  | -0.990  | 0.47     |
| IL-2α    | 59.6       | 20.0 | 56.3       | 22.2 | 0.579   | 0.76     |
| IL-3     | 17.1       | 16.6 | 17.3       | 9.9  | -0.051  | 0.96     |
| IL-12 (p40) | 43.4   | 23.2 | 56.2       | 26.8 | -1.907  | 0.15     |
| IL-16    | 210.8      | 90.0 | 220.6      | 73.1 | -0.447  | 0.63     |
| IL-18    | 60.3       | 24.3 | 61.3       | 17.2 | -0.171  | 0.93     |
| LIF      | BDR        | BDR  |            |      |         |          |
| MCP-3    | 7.2        | 3.4  | 5.8        | 3.7  | 1.443   | 0.30     |
| M-CSF    | 10.7       | 7.2  | 13.2       | 7.6  | -1.259  | 0.25     |
| MIF      | 78.3       | 31.3 | 81.0       | 28.1 | -0.333  | 0.88     |
| MIG      | 415.2      | 270.8 | 471.3     | 520.5 | -0.555 | 0.80     |
| îNGF     | 3.1        | 1.9  | 3.1        | 1.0  | 0.059   | 0.98     |
| SCF      | 144.0      | 24.3 | 150.3      | 39.3 | -0.718  | 0.68     |
| SCGF-β   | 29762.4    | 6331.6 | 32684.0   | 5613.8 | -1.827 | 0.16     |
| SDF-1α   | 162.7      | 55.7 | 180.8      | 43.6 | -1.347  | 0.33     |
related immune responses [23]. In this study, plasma levels of IL-1β in subjects with ASD were significantly and positively correlated with those of IL-1RA, suggesting that IL-1RA might have increased as a negative feedback regulator in response to the elevation of IL-1β levels in ASD.

Increases in plasma levels of IL-5, IL-13 and IL-12p70 in ASD

IL-5 is mainly produced by T helper 2 (Th2) cells and mast cells, and belongs to the Th2 cytokine family [25]. IL-5 stimulates B cells to secrete immunoglobulins and is also a mediator of eosinophil differentiation and activation. Previous studies have reported eosinophilia in children with autism [26,27], though a negative result has also been reported [28]. IL-13 is another Th2 cytokine that stimulates B cells to secrete IgE, which is an important mediator of allergic inflammation. A trend toward elevation in plasma levels of IL-4, the major Th2 cytokine, was also observed in the current study (t = −2.49, corrected P = 0.06, see Table 2). In contrast, plasma levels of IFN-γ and IL-2, which are Th1 cytokines, were similar between subjects with ASD and controls. Plasma levels of IL-2 and IFN-γ have been reported to be increased in autism (n = 20, mean age = 10.7 years) [17]. However, since none of the other studies found elevations of IL-2 or IFN-γ in peripheral samples [9,11,14,18], it was suggested that elevation of these Th1 cytokines may not be common in subjects with ASD. Our findings of increased levels of Th2 cytokines without corresponding changes in Th1 cytokines were consistent with previous in vitro studies which demonstrated Th2-preferred responses after stimulation in peripheral blood monocytes from subjects with ASD [26,29]. Since Th2 cells have been shown to play a role in the pathogenesis of allergy [30], our current findings are not inconsistent with the fact that allergy is a common clinical problem in individuals with ASD [31,32].

Table 2. Cont.

| Analytes    | Control group (n=28) | ASD group (n=28) | FDR-corrected P value |
|-------------|----------------------|------------------|-----------------------|
|             | mean                 | SD               | mean                  | SD         | t value |                   |
| TNF-β       | 3.4                  | 4.6              | 3.1                   | 3.4        | 0.285   | 0.88               |
| TRAIL       | 160.7                | 58.9             | 133.9                 | 48.9       | 1.851   | 0.16               |

Concentrations of analytes are shown in [pg/ml]. Note the statistically significant difference between the two groups (*P<0.05 after FDR correction for multiple comparisons). Abbreviations: ASD, autism spectrum disorder; BDR, below the detection range; FDR, false discovery rate; and SD, standard deviation.

doi:10.1371/journal.pone.0020470.t002

Figure 1. Fold changes of analytes measured by multiplex assay kits in subjects with autism spectrum disorder. The results represent the % concentration relative to the mean concentration of each analyte in the control group (dashed line in red). Data are expressed as the mean plus standard error of the mean.

doi:10.1371/journal.pone.0020470.g001
IL-12(p70) is a heterodimeric cytokine that consists of two subunits, p35 and p40 [33]. Our current finding of elevated plasma levels of IL-12(p70) is consistent with previous results in children with autism [17] and adults with Asperger’s syndrome [11]. IL-12(p40) has also been shown to be increased in the plasma of children with ASD [14]. IL-12(p70) is an immunoregulatory cytokine that is produced mainly by B cells and by monocytes, and is involved in the differentiation of naïve T cells into Th1 cells [33]. The elevated levels of plasma IL-12 in ASD might be an unsuccessful compensation for the above-mentioned Th1/Th2 imbalance in subjects with ASD.

Increased plasma levels of IL-17, IL-8 and GRO-α in ASD

Outside the Th1/Th2 cell paradigm, a distinct T helper cell subset that produces IL-17 has recently been discovered, and is known as the Th17 cell subset [34]. Th17 cells are responsive to IL-23 and secrete IL-17. Enstrom and his colleagues [15] have reported that plasma IL-17 levels in 2- to 5-year-old children with autism were similar to those in controls, but the IL-23 levels were decreased in the children with autism. Researchers from the same group also examined peripheral blood monocytes from subjects with ASD and found that PHA-stimulated release of IL-23, but not IL-17, was lower in subjects with ASD than in controls [35]. The discrepancy between our study and the previous report by Enstrom et al. [15] presumably reflects the differences in the age of participants and experimental designs. In addition, because the kits we used for multiplex assay did not include IL-23 as an analyte, further studies will be needed to examine the effects of this factor. Interestingly enough, however, recent findings suggest that IL-17 plays an important role in Th17 cell differentiation and IL-17 secretion [36,37].

Both IL-8 and GRO-α are chemokinetic cytokines produced by macrophages and other cell types, such as epithelial and endothelial cells. These chemokinetic cytokines have chemotactic activity on neutrophils and play important roles in the innate immune response. Previous studies have examined IL-8 levels in plasma or serum, and found either increases [14] or no change [11,38] in peripheral IL-8 levels. With regard to GRO-α, there has been no report showing a significant difference as compared to controls. The reason why these chemokines are increased in subjects with ASD is currently unknown. However, IL-17 is known to be a potent mediator of production of IL-8 and GRO-α from epithelial cells [34]. Since IL-8 and GRO-α function as chemotaxins of these chemokines, their elevation in the peripheral circulation suggests an activation of innate immunity. That is, the elevation in plasma IL-8 and GRO-α might have resulted from IL-17 secretion by Th17 cells activated in response to subclinical infections in epithelial or endothelial cells in our subjects with ASD.

Limitations

There were limitations in the present study. The small sample size renders the data presented here preliminary, and a larger study with more subjects with ASD will be necessary. However, recruitment for the current study was limited to a group of high-functioning subjects with ASD, none of whom were given psychotropic drugs. Therefore, our data are free from possible confounding factors and thus reflect a certain common immunological pathology among people with ASD.

Materials and Methods

Subjects

Twenty-eight male subjects with ASD and 28 healthy male controls participated in this study. All the participants were Japanese, born and living in restricted areas of central Japan, including Aichi, Gifu, and Shizuoka prefectures. Based on interviews and available information, including hospital records, diagnoses of ASD were made by an experienced child psychiatrist (TS) based on the DSM-IV-TR criteria [1]. The ADI-R [22] was also conducted by two of the authors (KJT and KM), both of whom have an established reliability of diagnosing autism with the Japanese version of ADI-R. ADI-R is a semi-structured interview conducted with a parent, usually the mother, and is used to confirm the diagnosis and also to evaluate the core symptoms of ASD. The ADI-R domain A score quantifies impairment in social interaction, the domain BV score quantifies impairment in communication, and the domain C score quantifies restricted, repetitive and stereotyped patterns of behavior and interests. The ADI-R domain D corresponds to the age of onset criterion for autistic disorder. We also used the third edition of the Wechsler Intelligence Scale for Children [39] to evaluate the intelligence quotient (IQ) of all the participants. Co-morbid psychiatric illnesses were excluded by means of the Structured Clinical Interview for DSM-IV (SCID) [40]. Participants were excluded from the study if they had any symptoms of inflammation, a diagnosis of fragile X syndrome, epileptic seizures, obsessive-compulsive disorder, affective disorders, IQ of lower than 70, or any additional psychiatric or neurological diagnoses. None of the participants had ever received psychoactive medications before this study. Healthy control subjects were recruited locally by advertisement. All control subjects underwent a comprehensive assessment of their medical history to eliminate individuals with any neurological or other medical disorders. SCID was also conducted to scrutinize any personal or family history of past or present mental illness. None of the comparison subjects initially recruited was found to fulfill any of these exclusion criteria. This study was approved by the ethics committee of the Hamamatsu University School of Medicine. All participants as well as their guardians were given a complete description of the study, and provided written informed consent before enrollment.

Blood sampling and multiplex assay

Fasting blood samples from all the participants were obtained between 11:00 and noon by venipuncture and collected into EDTA-containing tubes. Immediately after the sampling, samples were centrifuged for 10 min at 4°C, divided into 200-μl aliquots, and stored at −80°C until use. The mean time interval for preparation of plasma from blood samples was 4.5 min (3 to 6 min). Multiplex kits for measuring cytokines and chemokines were purchased from Bio-Rad (Bio-Plex Pro Human Cytokine Group I [27-plex] and Group II [21-plex] panels; Bio-Rad, Hercules, CA). The kits were used per the manufacturer’s instructions. Plasma samples were diluted using the appropriate sample diluents provided in each kit in accordance with the manufacturer’s instructions. Concentrations (pg/ml) of different analytes in the plasma samples were determined by using the standard curves generated in the multiplex assays. Each standard curve was generated using eight points of concentrations, and a nonlinear least squares minimization algorithm was used for the curve fitting by the five-parameter logistic equation and to determine the higher and low limits of detection. Data points for analytes that were occasionally above or below the detection range were discarded.

Data analysis

Comparisons of concentrations of analytes between subjects with ASD and controls were made by an unpaired t-test after confirming that there were no statistically significant differences in
variance as assessed by the F test. A P value of less than 0.05 was considered to be statistically significant after adjustment for the false discovery rate (FDR) for multiple comparisons using the Benjamin-Hochberg procedure. Evaluation of relationships between plasma levels of analytes and clinical variables among subjects with autism spectrum disorder was performed with Pearson’s r correlation coefficient. In the correlation analysis, values of P<0.05 were regarded as statistically significant. All statistical analyses were performed using SPSS statistics software (version 17; SPSS K.K., Tokyo, Japan).

Acknowledgments

The authors thank Ms. Tae Takahashi, Erina Sakamoto, and Mika Oyaizu for their excellent technical assistance.

Author Contributions

Conceived and designed the experiments: KS MT TS NM. Performed the experiments: HM KI YK CS. Analyzed the data: KJT YI KN. Wrote the paper: KS NM. Obtained informed consent from participants: SK YY TW KT ST KM.

References

1. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders. Fourth edition, text revision. Washington, DC: American Psychiatric Association.
2. Lichtenstein P, Carlström E, Råstam M, Gillberg C, Ankarsäter H (2010) The genetics of autism spectrum disorders and related neurodevelopmental disorders in childhood. Am J Psychiatry 167: 1357–1363.
3. Ashwood P, Wilk S, Van de Water J (2006) The immune response in autism: a new frontier for autism research. J Leukoc Biol 80: 1–15.
4. Zimmerman AW (2006) The Immune System. In: The Neurobiology of Autism, second edition. Bauman ML, Kemper TL, eds. Baltimore, ML: The Johns Hopkins University Press.
5. Li X, Chauhan A, Sheikh AM, Patil S, Chauhan V, et al. (2009) Elevated immune response in the brain of autistic patients. J Neuroimmunol 207: 111–116.
6. Vargas DL, Nasimbene C, Krishnan C, Zimmerman AW, Pardo CA (2005) Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 57: 67–81.
7. Jyonouchi H, Sun S, Le H (2001) Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunol 120: 170–179.
8. Corbett BA, Kantor AB, Schulman H, Walker WL, Lit L, et al. (2007) A protéome study of serum from children with autism showing differential expression of apolipoproteins and complement proteins. Mol Psychiatry 12: 292–306.
9. Croonenberghs J, Bosmans E, Deboosse D, Keriv G, Maes M (2002) Activation of the inflammatory response system in autism. Neuropsychobiology 45: 1–6.
10. Croonenberghs J, Wauters A, Devreese K, Verkerk R, Scharpe S, et al. (2002) Increased serum albumin, gamma globulin, immunoglobulin IgG, and IgG2 and IgG4 in autism. Psychol Med 32: 1457–1463.
11. Schwarz E, Guest PG, Rahmoun E, Wang L, Levin Y, et al. (2010) Sex-specific serum biomarker patterns in adults with Asperger’s syndrome. Mol Psychiatry; (Published online on Sep. 20, 2010).
12. Singh VR, Warren RP, Odel JL, Cole P (1991) Changes of soluble interleukin-2, interleukin-2 receptor, T helper, and interleukin-1 in the serum of autistic children. Clin Immunol Immunopathol 61: 440–455.
13. Zimmerman AW, Jyonouchi H, Comi AM, Conners SL, Milstein S, et al. (2005) Cerebrospinal fluid and serum markers of inflammation in autism. Pediatr Neurol 33: 195–201.
14. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, et al. (2011) Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav Immun 25: 40–45.
15. Enstrom A, Ounoo C, Hertz-Picciotto I, Hansen R, Croen L, et al. (2008) Detection of IL-17 and IL-23 in Plasma Samples of Children with Autism. Am J Biomech Biotech 8: 114–120.
16. Grigorenko EL, Han SS, Yrisogun CM, Leng I, Mizez Y, et al. (2008) Macrophage migration inhibitory factor and autism spectrum disorders. Pediatrics 122: e430–e435.
17. Singh VR (1996) Plasma increase of interleukin-12 and interferon-gamma. Pathological significance in autism. J Neuroimmunol 66: 143–145.
18. Sweezen TL, Posey DJ, Shankar S, McDougle CJ (2006) High nitric oxide production in autistic disorder: a possible role for interferon-gamma. Biol Psychiatry 55: 434–437.
19. Di Nizio M, Niers TM, Reitman PH, Buller HR (2005) Plasma cytokine and P-selectin levels in advanced malignancy: prognostic value and impact of low-molecular weight heparin administration. Cancer 104: 2275–2281.
20. Hart JP, Broadwater G, Rabbani Z, Moeller BJ, Clough R, et al. (2005) Cytokine profiling for prediction of symptomatic radiation-induced lung injury. Int J Radiat Oncol Biol Phys 63: 1448–1454.
21. Fujita-Shimizu A, Suzuki K, Nakamura K, Miyachi T, Matsuzaki H, et al. (2010) Decreased serum levels of adiponectin in subjects with autism. Prog Neuropharmacol Biol Psychiatry 34: 455–458.
22. Lord C, Rutter M, Le Couteur A (1994) Autism diagnostic interview-revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 24: 659–665.
23. Norena MG, Simon A, van de Veerdonk F, Kullberg BJ, Van der Meer JW, et al. (2010) IL-1beta processing in host defense: beyond the inflammation. PLoS Pathog 6: e1000661.
24. Emanuele E, Orsi P, Boso M, Broglio D, Brindino N, et al. (2010) Low-grade endostinoma in patients with severe autism. Neurosci Lett 471: 162–165.
25. Lloyd CM, Hessel EM (2010) Functions of T cells in asthma: more than just T(H)2 cells. Nat Rev Immunol 10: 838–848.
26. Molloy CA, Morrow AL, Meiren-Dear J, Schleifer K, Dinenger K, et al. (2006) Elevated cytokine levels in children with autism spectrum disorder. J Neuroimmunol 172: 198–205.
27. Renzoni E, Beltrami V, Sestini P, Pomplua A, Menchetti G, et al. (1993) Brief report: allergological evaluation of children with autism. J Autism Dev Disord 25: 327–333.
28. Sweetin TL, Posey DJ, McDougle C (2003) High blood monocyte counts and neopterin levels in children with autistic disorder. Am J Psychiatry 160: 1601–1603.
29. Gupta S, Aggarwal S, Rastanavar B, Lee T (1990) Th1- and Th2-like cytokines in CD4+ and CD8+ T cells in autism. J Neuroimmunol 85: 106–109.
30. Nakajima H, Takatsu K (2007) Role of cytokines in allergic airway inflammation. Int Arch Allergy Immunol 142: 263–273.
31. Magañes ES, Pinto-Marin F, Bustos-Pinto S, Pontes AT, Prado EA, et al. (2009) Immune allergic response in Asperger syndrome. J Neuroimmunol 216: 101–112.
32. Theoharides TC, Angelidou A, Alysandratos KD, Zhang B, Asadi S, et al. (2010) Mast cell activation and autism. Biochim Biophys Acta; (Published online on Dec 28, 2010).
33. Trianchi G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3: 133–146.
34. Eyriech S, Eyriech K, Cavani A, Schmidt-Weber C (2010) IL-17 and IL-22: mast cell activation and autism. Biochim Biophys Acta (Published online on Sep. 20, 2010).
35. Onore C, Enstrom A, Krakowiak P, Hertz-Picciotto I, Hansen R, et al. (2009) Decreased cellular IL-23 but not IL-17 production in children with autism spectrum disorders. J Neuroimmunol 216: 126–129.
36. Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, et al. (2009) Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 30: 576–587.
37. Li L, Kim J, Boussios VA (2010) IL-1β-mediated signals preferentially drive conversion of regulatory T cells but not conventional T cells into IL-17-producing cells. J Immunol 185: 4146–4153.
38. Nelson PG, Kaddoo T, Song YJ, Bambruna JM, Kohler S, et al. (2006) Selected neurotrophins, neuropeptides, and cytokines: developmental trajectory and concentrations in neonatal blood of children with autism or Down syndrome. Int J Dev Neurosci 24: 73–80.
39. Wechsler D (1997) Wechsler Intelligence Scale for Children Third Edition manual. New York, NY: The Psychological Corporation.
40. American Psychiatric Association (1997) User’s guide for the structured clinical interview for DSM-IV axis I disorders SCID-1: clinician version. Washington, DC: American Psychiatric Press.